Summary A randomised trial has previously been repeated in which 437 women with node positive breast cancer received either a 12-week chemohormonal regimen consisting of cyclophosphamide, methotrexate, fluorouracil, vincristine, prednisone, adriamycin and tamoxifen or 36 weeks of CMFVP. The present analysis concerns the local recurrence rates for the 122 lumpectomy patients who did not receive breast irradiation. The cumulative rate of local breast recurrence was greater in the 12-week than the 36-week group, P = 0.02. Similarly, in the lumpectomy patients, the cumulative rate of distant recurrence was greater in the 12-week than the 36-week group, P = 0.04. In conclusion, our results suggest that adjuvant chemotherapy impacts on local breast recurrence in a similar manner to other sites in Stage II breast cancer patients treated by lumpectomy without radiation. Despite the use of a conventional 36-week adjuvant chemotherapy regimen, the local breast recurrence rate was substantial.
In recent years, based on the results of clinical trials, breast conserving surgery has increased in popularity as the primary surgical management for patients with operable breast cancer (Veronesi et al., 1981; Fisher et al., 1985; Fisher et al., 1989; Hayward, 1977; Veronesi, 1985 . In a trial from the Milan Cancer Institute, 701 women with clinical Stage I or Stage II breast cancer were randomised to either Halstead radical mastectomy or quadrantectomy and axillary dissection plus local irradiation to the breast (Veronesi et al., 1981) . No significant difference in survival was detected between the treatment groups. The NSABP conducted trial B-06, in which 1,843 women with Stage I or II breast cancer were randomised to either modified radical mastectomy, lumpectomy plus axillary dissection plus local breast irradiation, or lumpectomy plus axillary dissection alone (Fisher et al., 1985 (Fisher et al., , 1989 . No difference was detected in terms of overall survival among the three treatment groups. In this trial however, lumpectomy patients who received the local breast irradiation had a substantial reduction in local breast recurrence compared to non-irradiated patients (39% to 10%) at 8 years of follow-up.
Based on the results of this trial and some non-randomised studies (Cale, 1985; Pierquin, 1985; Botnick, 1985, radiation to the breast has become standard practice in women undergoing lumpectomy. We have previously reported the results of a randomised trial in which women with Stage II breast cancer received either a 12-week chemohormonal regimen or 36 weeks of adjuvant chemotherapy (Levine et al., 1990) . The 12-week treatment was found to be inferior to the 36-week treatment both in terms of recurrence and survival. In this trial, women underwent mastectomy or lumpectomy prior to being randomised to one of the two alternative forms of adjuvant systemic therapy and no patients received postoperative breast irradiation. Thus, this trial has provided us with the opportunity to examine the effect of two different chemotherapy regimens on local breast recurrence in women who have undergone lumpectomy without breast irradiation.
Methods
A detailed description of the patient population, study design, treatment regimens, criteria for outcome assessment and details of patient follow-up have been previously reported (Levine et al., 1990) . Briefly, we studied patients under the age of 70 years with histologically confirmed axillary node-positive breast cancer who had undergone modified radical mastectomy or lumpectomy plus axillary dissection. The type of surgery was based on the referring surgeon's and patient's preferences. Patients were excluded from the study if they had residual tumour at the surgical margins of the lumpectomy. Informed consent was obtained from eligible patients before assignment to treatment.
The 12-week regimen consisted of cyclophosphamide 80 mg m-2 day-' orally for 8 weeks, methotrexate 35 mg m-2 and fluorouracil 500 mg m-2 both intravenously weekly for 8 weeks, vincristine mg m-2 weekly for 4 weeks and then every second week prednisone 50mg orally for 10 days and then tapered, adriamycin 20 mg m-2 weekly for weeks 9 through 12, and tamoxifen 10 mg orally twice daily throughout (CMFVP + AT). The 36-week regimen consisted of cyclophosphamide 80 mg m-2 day-' orally for 36 weeks, methotrexate 28 mg m2 and fluorouracil 500 mg m2 both intravenously weekly for 8 weeks and then every second week, vincristine 1.4 mg m2 weekly for 4 weeks and then monthly, and prednisone 30 mg m2 orally for 10 days and then tapered.
All local breast recurrences were confirmed histologically. Distant recurrence was designed as any recurrence other than a recurrence in the breast in which the original tumour had been removed by lumpectomy.
Statistical analysis
The outcomes of cumulative local breast recurrence, distant disease-free survival and overall survival were summarised as survival curves using the Kaplan-Meier method (Kaplan, 1958) . The survival curves of treatment groups were compared using the Mantel-Cox test (Mantel, 1966) . When comparing treatment effects, the Cox proportional hazards model was used to adjust for the influence of various prognostic factors including age, number of positive nodes, menopausal status, oestrogen receptor level, progesterone receptor level, and tumour size (Cox, 1972) . Tests for linear trend in proportions used Cochran's regression method (Cochran, 1954 Table I ). The cumulative rate of local breast recurrence as a first event was greater in the 12-week than than the 36-week group, P = 0.02 (Figure 1 ). When the Cox regression analysis was performed, which adjusted for any imbalances in baseline prognostic factors, the risk ratio for a local event in the 12-week compared to the 36-week group was 2.6 (P = 0.02).
For the lumpectomy patients, the cumulative rate of nonlocal breast recurrence (distant) was greater in the 12-week group than the 36-week group, 50% vs 33% respectively, at 48 months, P = 0.04. In the Cox regression analysis the risk ratio for a distant event in the 12-week group compared to the 36-week group was 1.4 (P = 0.02), and was of a similar order of magnitude in both the lumpectomy (1.9) and mastectomy (1.4) patients.
For lumpectomy -patients, the overall survival in the 36-week group was also greater than the 12-week group, but did not reach conventional levels of statistical significance, P = 0.29 (Figure 2 ). In the Cox analysis the risk ratio for a fatal event in the 12-week group compared to the 36-week group was 1.4 (P = 0.10), and was comparable in both the lumpectomy (1.6) and mastectomy (1.4) patients. The overall 
Management of local breast recurrences
The study protocol did not specify a standard form of management once a lumpectomy patient experienced a local breast recurrence. The management of a local recurrence in such patients is presented in Table II . Twenty-two (57%) of the patients went on to mastectomy, and eight (22%) had another lumpectomy. In four patients (11%), breast irradia- (Fisher et al., 1985 (Fisher et al., , 1989 (Levine et al., 1990) . The study also provided us with the opportunity to examine the impact of the two different regimens on the rates of local breast recurrence in lumpectomy patients.
The results of this analysis show that the rate of local breast recurrence, either as a first event or at any time, was greater in the 12-week patient group compared to the 36-week group. In addition for lumpectomy patients, the 12-week chemohormonal regimen was ineffective compared to 36 weeks of chemotherapy in controlling distant recurrence. Thus, in terms of the biology of breast cancer, the differing local recurrence rates between the two regimens provides evidence that adjuvant chemotherapy itself can impact on the rate of local breast recurrence in lumpectomy patients, in a similar manner to its effect on recurrence in other sites. The two treatment regimens in the trial differed in both drug content and duration. Possible explanations for the observed inferiority of the 12-week treatment for both local and distant recurrences were its shorter duration and/or a negative interaction of tamoxifen on the chemotherapy (Levine et al., 1990) .
The overall absolute rate of local breast recurrence (31%) in our lumpectomy patients was considerable at a median follow-up of 54 months. In the NSABP B-06 study, in the Stage II women, the rate of local breast recurrence was 6% in the irradiated group compared to 43% in the unirradiated group at 8 years of follow-up (Fisher et al., 1989) . All these Stage II patients received chemotherapy. Thus, although there are limitations in comparing between studies, our observed local breast recurrence rate is consistent with that in B-06. In addition, in the NSABP study the rate of local recurrence in the node negative patients who received radiation was 12%. The lower recurrence rate in the node positive irradiated patients compared to the node negative irradiated. patients was attributed to a possible synergistic effect between chemotherapy and radiation (Fisher et al., 1989) .
When the results of B-06 were published, recruitment to our trial was well along the way. Since no difference in overall survival was reported in B-06 and because of concern for interactions between radiation and chemotherapy, the study investigators in our trial decided not to introduce local breast irradiation.
In conclusion, our results suggest that adjuvant chemotherapy impacts on local breast recurrence in Stage II breast cancer patients treated by lumpectomy without radiation. Despite the use of a conventional 36-week adjuvant chemotherapy regimen, the local breast recurrence rate was substantial. It is possible that with improved adjuvant regimens, local recurrence in lumpectomy breasts may diminish, thus obviating the need for local breast irradiation. This, however, awaits the results of future trials and meanwhile local breast irradiation should continue as standard treatment for women with Stage II breast cancer who have undergone lumpectomy.
